As a result, several compounds have been developed to target nuclear import and export receptors197 and phase III clinical trials are under way targeting the KPNA/KPNB1 interface highjacked by viruses causing Dengue fever and COVID-19, respectively.196. Here, KPNB1 is linked to dengue disease.